Background. We aimed to assess the association of habitually eating in the late evening and skipping breakfast with the prevalence of overweight/obesity. Methods. A total of 19,687 Japanese women, aged 40–74 years, were asked about their height, weight, and habitual eating behaviors such as having a late dinner and a bedtime snack and skipping breakfast, using a self-administered questionnaire. We defined overweight/obesity as body mass index greater than or equal to 25 kg/m2. Results. Among the participants, 11% regularly had a late dinner, 22% had bedtime snacks, and 8% skipped breakfast. After adjusting for age, exercise, smoking, sleep duration, and employment, the multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of skipping breakfast were 2.47 (2.18–2.81) for having a late dinner and 1.71 (1.53–1.91) for having a bedtime snack. These eating behaviors were associated with an increased risk of overweight/obesity: the multivariable-adjusted ORs (95% CIs) of obesity/overweight were 1.43 (1.27–1.62) for having a late dinner, 1.47 (1.34–1.62) for having a bedtime snack, and 1.23 (1.06–1.42) for skipping breakfast. Conclusions. Japanese women who consumed late dinners or bedtime snacks were more likely to skip breakfast. Having a late dinner or bedtime snack was associated with a higher probability of overweight/obesity.

No abstract

Background: Fosaprepitant-associated injection site reaction (ISR) has been reported in patients treated with cisplatin, an irritant drug. We conducted this retrospective study to clarify the incidence and symptoms of fosaprepitant-associated ISR in patients treated with anthracycline.Patients and methods: Fifty six patients receiving 159 injections administering doxorubicin/cyclophosphamide (AC), fluorouracil/epirubicin/cyclophosphamide (FEC), or rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone (R-)CHOP regimen through a peripheral vein at ambulatory treatment centers reviewed for this study from patients' medical records. Incidence of ISR was compared between 24 patients with fosaprepitant injection (fosaprepitant group) and 32 patients without fosaprepitant (control group). Frequency and symptoms of ISR per injection were also compared between 61 injections with fosaprepitant and 98 injections without fosaprepitant.Results: Both the ISR incidence rate per patient and per injection were significantly higher in the fosaprepitant group than in the control group (67% vs. 16%; P=0.0002, 34% vs. 8.2%; P<0.0001, respectively). By multivariate analysis, fosaprepitant injection was found to be a significant independent variable correlated with ISR risk. Symptoms observed in 61 injections of fosaprepitant were pain (n=14, 23%), erythema (n=10, 16%), swelling (n=6, 10%), and delayed drip infusion (n=6, 10%). After the observation period, no ISR occurred when the administration route was changed to central venous injection or oral aprepitant was administered despite the continuation of chemotherapy.Conclusion: ISR occurred more frequently and severely when fosaprepitant was injected through the peripheral vein in patients treated with anthracyclines compared to those without fosaprepitant.

We have investigated to develop novel vaccines against SARS CoV using cDNA constructs encoding the structural antigen; spike protein (S), membrane protein (M), envelope protein (E), or nucleocapsid (N) protein, derived from SARS CoV. Mice vaccinated with SARS-N or -M DNA using pcDNA 3.1(+) plasmid vector showed T cell immune responses (CTL induction and proliferation) against N or M protein, respectively. CTL responses were also detected to SARS DNA-transfected type II alveolar epithelial cells (T7 cell clone), which are thought to be initial target cells for SARS virus infection in human. To determine whether these DNA vaccines could induce T cell immune responses in humans as well as in mice, SCID-PBL/hu mice was immunized with these DNA vaccines. As expected, virus-specific CTL responses and T cell proliferation were induced from human T cells. SARS-N and SARS-M DNA vaccines and SCID-PBL/hu mouse model will be important in the development of protective vaccines.